STOCK TITAN

Edesa Biotech: StemPoint reports 9.9% passive stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Edesa Biotech, Inc. (EDSA) was the subject of a Schedule 13G reporting shared beneficial ownership by StemPoint Capital LP, StemPoint Capital Management GP LLC and Michelle Ross. Each may be deemed to beneficially own the same 1,407,181 Common Shares, comprising 825,000 Common Shares and 582,181 shares through exercise of pre-funded warrants; this is not a combined total across the three reporting persons. The reported 9.9% was rounded down. Its calculation used 13,503,723 Common Shares believed outstanding, as disclosed in the issuer’s Prospectus Supplement filed August 20, 2026, plus 582,181 warrant shares. A 9.99% beneficial ownership limitation applies; the calculation excludes 242,819 additional shares underlying the warrants.

Beneficial ownership amount 1,407,181 shares Each reporting person may be deemed to beneficially own this amount; the reported amount comprises Common Shares and shares through exercise of pre-funded warrants.
Common Shares held 825,000 shares Component of the amount each reporting person may be deemed to beneficially own.
Shares through pre-funded warrants 582,181 shares Included in the beneficial ownership amount and in the percentage calculation.
Reported ownership percentage 9.9% Cover-page percentage, rounded down.
Beneficial ownership limitation 9.99% Limitation applicable to the pre-funded warrants.
Common Shares believed outstanding 13,503,723 shares Amount cited from the issuer’s Prospectus Supplement filed August 20, 2026; 582,181 warrant shares were added for the reported percentage calculation.
Excluded shares underlying warrants 242,819 shares Shares underlying the pre-funded warrants excluded from the percentage calculation due to the beneficial ownership limitation.
beneficial ownership limitation regulatory
"subject to a beneficial ownership limitation of 9.99%"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
Pre-Funded Warrants financial
"582,181 shares of Common Shares through the exercise of the Pre-Funded Warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
shared voting power regulatory
"Shared voting power: 1,407,181"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared dispositive power: 1,407,181"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Edesa Biotech shares do StemPoint and Michelle Ross report?

StemPoint Capital LP, StemPoint Capital Management GP LLC and Michelle Ross each may be deemed to beneficially own 1,407,181 Edesa Biotech Common Shares. That amount consists of 825,000 Common Shares and 582,181 shares through exercise of pre-funded warrants; it is the same reported position for each, not an aggregate across them.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





27966L306

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G




Comment for Type of Reporting Person: StemPoint Capital Management GP LLC is a limited liability company.


SCHEDULE 13G





SCHEDULE 13G



StemPoint Capital LP
Signature:/s/ Sean C. Tan
Name/Title:Sean C. Tan, Authorized Signatory
Date:11/16/2026
StemPoint Capital Management GP LLC
Signature:/s/ Sean C. Tan
Name/Title:Sean C. Tan, Authorized Signatory
Date:11/16/2026
Michelle Ross
Signature:/s/ Michelle Ross
Name/Title:Michelle Ross
Date:11/16/2026
Exhibit Information

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

Keep reading